SCHEMBL2231665

SCHEMBL2231665

Cc1cccc[n+]1CC(=O)c1ccccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
THRB P10828 1/20 0.47
ERCC5 P28715 1/20 0.45
FEN1 P39748 1/20 0.45
RAB9A P51151 4/20 0.44
MEN1 O00255 3/20 0.44
LMNA P02545 2/20 0.44
CYP2C19 P33261 1/20 0.44
KDM4E B2RXH2 1/20 0.44
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
ALDH1A1 P00352 3/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
POLB P06746 2/20 0.41
NPC1 O15118 2/20 0.41
MAPT P10636 3/20 0.40
CXCR3 P49682 1/20 0.39
MMP14 P50281 1/20 0.38
HPGD P15428 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1647384 0.98 KMT2A (0.55) KMT2ATHRBERCC5FEN1RAB9A
Bromide SCHEMBL3890738 0.83 KMT2A (0.57) KMT2ATHRBERCC5FEN1RAB9A
Bromide SCHEMBL3890163 0.80 KMT2A (0.49) KMT2ATHRBRAB9AMEN1LMNA
Bromide SCHEMBL3897209 0.78 KMT2A (0.63) KMT2ATHRBRAB9AMEN1LMNA
SCHEMBL13394254 0.77 KMT2A (0.70) KMT2ATHRBRAB9AMEN1LMNA
Bromide SCHEMBL1647594 0.77 KMT2A (0.51) KMT2ATHRBRAB9AMEN1LMNA
SCHEMBL7996595 0.77 KMT2A (0.48) KMT2ATHRBRAB9AMEN1LMNA
Bromide SCHEMBL1645919 0.76 KMT2A (0.73) KMT2ATHRBRAB9AMEN1LMNA
SCHEMBL4890283 0.75 THRB (0.56) KMT2ATHRBERCC5FEN1MEN1
SCHEMBL8120684 0.74 KMT2A (0.54) KMT2ATHRBRAB9AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8604029-B2 2-[(2-substituted)-indolizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD BRITISH BODY CORPORATE (GB) 2013-12-10 US disclosed
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD. 2010-03-04 US disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 KMT2A 603/4885THRB 2955/4885ERCC5 4868/4885
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 KMT2A 3693/4885THRB 3738/4885ERCC5 4463/4885
US-20100056511-A1 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS NAT1, AGXT, CYP1A2 KMT2A 1472/4885THRB 3788/4885ERCC5 4775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.